Activin and estrogen crosstalk regulates transcription in human breast cancer cells

被引:36
作者
Burdette, Joanna E.
Woodruff, Teresa K. [1 ]
机构
[1] Northwestern Univ, Feinberg Coll Med, Inst Womens Hlth Res, Chicago, IL 60611 USA
[2] Northwestern Univ, Ctr Reprod Sci, Evanston, IL 60208 USA
[3] Northwestern Univ, Ctr Reprod Sci, Chicago, IL 60208 USA
[4] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
关键词
D O I
10.1677/ERC-07-0054
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Activin is a member of the transforming growth factor beta superfamily that regulates mammary cell function during development, lactation, and in cancer. Activin slows the growth of breast cancer cells by inducing G(0)/G(1) cell cycle arrest. Estrogen is a steroid hormone that stimulates the proliferation of mammary epithelial cells in development and oncogenesis. The crosstalk between estrogen and activin that regulates activin ligand expression, activin and estrogen signal transduction, and cell cycle arrest was investigated in this study. Estrogen antagonized activindependent production of plasminogen activator inhibitor 1 (PAI-1) mRNA, while activin repressed estrogen-dependent transcription of trefoil factor 1. The repression of estrogen signaling by activin was recapitulated using a simple estrogen response element-luciferase construct and was enhanced in the presence of overexpressed estrogen receptor g, (ER alpha). In contrast, estrogen-mediated repression of activin signaling could not be recapitulated on a simple CAGA Smad-binding element but did inhibit the short PAI-1 promoter, p3TP-luciferase, especially when ERa was overexpressed. Repression of both estrogen- and activin-regulated transcription was found to be ligand induced and Smad3 dependent. In addition to transcriptional repression, estrogen also reduced the amount of activin B mRNA and protein produced by MCF7 breast cancer cells. These studies demonstrate the importance of activin and estrogen crosstalk during mammary cell growth and cancer initiation.
引用
收藏
页码:679 / 689
页数:11
相关论文
共 48 条
[1]   Progesterone receptors - animal models and cell signaling in breast cancer - The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis [J].
Anderson, E .
BREAST CANCER RESEARCH, 2002, 4 (05) :197-201
[2]   Estrogen receptors as therapeutic targets in breast cancer [J].
Ariazi, Eric A. ;
Ariazi, Jennifer L. ;
Cordera, Fernando ;
Jordan, V. Craig .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2006, 6 (03) :181-202
[3]   Reversal of tamoxifen resistance of human breast carcinomas in vivo by neutralizing antibodies to transforming growth factor-β [J].
Arteaga, CL ;
Koli, KM ;
Dugger, TC ;
Clarke, R .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1999, 91 (01) :46-53
[4]  
Brandt S, 2003, ANTICANCER RES, V23, P223
[5]   Antiestrogens induce growth inhibition by sequential activation of p38 mitogen-activated protein kinase and transforming growth factor-β pathways in human breast cancer cells [J].
Buck, MB ;
Pfizenmaier, K ;
Knabbe, C .
MOLECULAR ENDOCRINOLOGY, 2004, 18 (07) :1643-1657
[6]   Activin A mediates growth inhibition and cell cycle arrest through smads in human breast cancer cells [J].
Burdette, JE ;
Jeruss, JS ;
Kurley, SJ ;
Lee, EJ ;
Woodruff, TK .
CANCER RESEARCH, 2005, 65 (17) :7968-7975
[7]   Activin and follistatin in rat mammary gland [J].
Bussmann, UA ;
Lanuza, GM ;
Bussmann, LE .
MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2004, 221 (1-2) :9-19
[8]   Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling [J].
Clarke, R ;
Liu, MC ;
Bouker, KB ;
Gu, ZP ;
Lee, RY ;
Zhu, YL ;
Skaar, TC ;
Gomez, B ;
O'Brien, K ;
Wang, Y ;
Hilakivi-Clarke, L .
ONCOGENE, 2003, 22 (47) :7316-7339
[9]   The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin [J].
Cocolakis, E ;
Lemay, S ;
Ali, S ;
Lebrun, JJ .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (21) :18430-18436
[10]   Tissue-type plasminogen activator (tPA) in breast cancer:: relationship with clinicopathological parameters and prognostic significance [J].
Corte, MD ;
Vérez, P ;
Rodríguez, JC ;
Roibás, A ;
Domínguez, ML ;
Lamelas, ML ;
Vázquez, J ;
Muñiz, JLG ;
Allende, MT ;
González, LO ;
Fueyo, A ;
Vizoso, F .
BREAST CANCER RESEARCH AND TREATMENT, 2005, 90 (01) :33-40